Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01845792 · ClinicalTrials.gov registry record · Phase 2
Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer
A Phase 2 study, sponsored by University of Colorado, Denver.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT01845792 is a Phase 2 study that was terminated before completion, run by University of Colorado, Denver. The registered enrollment target is 7 participants.
The verdict
NCT01845792, a Phase 2 study, was terminated before completion, sponsored by University of Colorado, Denver.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
Patients are being asked to take place in this research study because they have advanced prostate cancer that has gotten worse after other treatments. If they join this study they will receive a new combination of drugs that are used to treat prostate cancer.
Interventions
- DRUG Cabazitaxel
- DRUG Cabazitaxel with Abiraterone Acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2013-07 |
| Est. Completion | 2017-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01845792
The ClinicalTrials.gov registry entry for NCT01845792 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cabazitaxel is the first listed.
NCT01845792 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01845792 about?
NCT01845792 is a clinical study titled "Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer". Patients are being asked to take place in this research study because they have advanced prostate cancer that has gotten worse after other treatments. If they join this study they will receive a new combination of drugs that are used to treat prostate cancer.
What is the current status of trial NCT01845792?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2013-07. Estimated completion is 2017-02.
What interventions are being tested in trial NCT01845792?
The interventions under investigation include: Cabazitaxel (DRUG), Cabazitaxel with Abiraterone Acetate (DRUG).
Who is sponsoring clinical trial NCT01845792?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.